Deals In Depth: May 2013
Executive Summary
AbbVie paid $70 million up front in an option-based deal with Alvine, and both Valeant and Actavis completed $8 billion-plus acquisitions, of B&L and Warner Chilcott, respectively. IPOs accounted for $1 billion of the $2.7 billion in biopharma financing; device firms raised $342 million.